期刊文献+

Effects of Shenlian Extracts (参莲提取物) on Atherosclerosis by Inhibition of the Inflammatory Response 被引量:3

Effects of Shenlian Extracts (参莲提取物) on Atherosclerosis by Inhibition of the Inflammatory Response
原文传递
导出
摘要 Objective: Inflammation plays a critical role in atherosclerosis, and this inflammatory reaction is being intensively studied. Shenlian Extracts (参莲提取物), an active ingredient of Chinese medicinal herbs, is believed to have multiple therapeutic and preventive effects against human vascular diseases, including atherosclerosis. Our work investigated whether Shenlian Extracts serves as an anti-inflammatory agent during atherogenesis. Methods: We established a model of atherosclerosis in rabbits using balloon angioplasty and a high cholesterol diet. The effects of Shenlian Extracts on vessel structure and inflammation were assessed by hematoxylin-eosin staining of the femoral artery, measurement of inflammation-related factors in serum or vascular tissue, and radioimmunoassay. Enzyme linked immunosorbent assays (ELISA), flow cytometry and western blots were also performed. Results: We show that oral pre-treatment with Shenlian Extracts suppressed the pathological changes associated with atherosclerosis and that graded doses of Shenlian Extracts reduced total serum levels of cholesterol (90, 180 and 360 mg/kg), triglyceride (180 and 360 mg/kg), and LDL-c (90, 180 mg/kg). Various doses of Shenlian Extracts reduced serum content of TNF-α (180 and 360 mg/kg), CRP (90, 180 and 360 mg/kg) and IL-8 (360 mg/kg) (P<0.05), but led to no significant changes in IL-1β levels. Treatment with Shenlian Extracts also significantly reduced VCAM-1 levels (90 and 360 mg/kg) and IGF-1 levels (90 and 180 mg/kg) in vascular tissue but had no significant effect on ICAM-1 and MCP-1 levels. Finally, Shenlian Extracts significantly reduced the abnormal expression of CD18 in monocytes in a dose-dependent manner. Conclusion: These results suggest that Shenlian Extracts may play a direct role in preventing and treating atherogenesis by inhibiting the inflammatory reaction, providing insights into the possible mechanism underlying the anti-atherosclerotic actions of Shenlian Extracts. Objective: Inflammation plays a critical role in atherosclerosis, and this inflammatory reaction is being intensively studied. Shenlian Extracts (参莲提取物), an active ingredient of Chinese medicinal herbs, is believed to have multiple therapeutic and preventive effects against human vascular diseases, including atherosclerosis. Our work investigated whether Shenlian Extracts serves as an anti-inflammatory agent during atherogenesis. Methods: We established a model of atherosclerosis in rabbits using balloon angioplasty and a high cholesterol diet. The effects of Shenlian Extracts on vessel structure and inflammation were assessed by hematoxylin-eosin staining of the femoral artery, measurement of inflammation-related factors in serum or vascular tissue, and radioimmunoassay. Enzyme linked immunosorbent assays (ELISA), flow cytometry and western blots were also performed. Results: We show that oral pre-treatment with Shenlian Extracts suppressed the pathological changes associated with atherosclerosis and that graded doses of Shenlian Extracts reduced total serum levels of cholesterol (90, 180 and 360 mg/kg), triglyceride (180 and 360 mg/kg), and LDL-c (90, 180 mg/kg). Various doses of Shenlian Extracts reduced serum content of TNF-α (180 and 360 mg/kg), CRP (90, 180 and 360 mg/kg) and IL-8 (360 mg/kg) (P〈0.05), but led to no significant changes in IL-1β levels. Treatment with Shenlian Extracts also significantly reduced VCAM-1 levels (90 and 360 mg/kg) and IGF-1 levels (90 and 180 mg/kg) in vascular tissue but had no significant effect on ICAM-1 and MCP-1 levels. Finally, Shenlian Extracts significantly reduced the abnormal expression of CD18 in monocytes in a dose-dependent manner. Conclusion: These results suggest that Shenlian Extracts may play a direct role in preventing and treating atherogenesis by inhibiting the inflammatory reaction, providing insights into the possible mechanism underlying the anti-atherosclerotic actions of Shenlian Extracts
出处 《Journal of Traditional Chinese Medicine》 SCIE CAS CSCD 2011年第4期344-348,共5页 中医杂志(英文版)
基金 supported by grants of the National Natural Science Foundation of China (30973901) the Major Program for Technique Development Research of Novel Traditional Chinese Medicine Production (2009 ZX093 01-005- 2-4) the Autonomous Program of China Academy of Chinese Medical Sciences (ZZ20090207) the International S&T Cooperation Project (S2011ZR0193)
关键词 Traditional Chinese Medicine Shenlian Extracts atherosclerosis inflammatory pathology lipid inflammatory factor adhesion factor growth factor 动脉粥样硬化 炎症反应 提取物 胆固醇水平 酶联免疫吸附试验 血管疾病 VCAM-1 ICAM-1
  • 相关文献

参考文献17

二级参考文献47

共引文献377

同被引文献29

引证文献3

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部